 The maternal ARV regimen will be initiated as soon as possible from 20 weeks of gestation until at least the cessation of breastfeeding with the advice to cease at six months. The decision to stop or continue the maternal ARV regimen after breastfeeding cessation will be based on the baseline maternal CD4 count and the maternal clinical stage at baseline andor at breastfeeding cessation. A woman with a baseline CD4 500 cellsml will always be proposed to continue her treatment after breastfeeding cessation. A woman with a baseline CD4 count 500 will be asked to stop her treatment after breastfeeding cessation unless she has reached the WHO clinical stage IV at that time. 